Subcutaneous formulation off to an encouraging start; R&D pipeline progressing well
13/08/20 -"Despite being slightly impacted by COVID-19 in Q2, Darzalex continued to gain share in the multiple myeloma market. Given the encouraging launch of the subcutaneous formulation, we anticipate a ..."
Pages
49
Language
English
Published on
13/08/20
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated